Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT05497284) enrolled 46 people in total — 23 received a treatment called LTP001 (at a 6mg dose) and 23 received a placebo (a dummy treatment with no active ingredient). The trial was looking at changes in lung function over a treatment period, primarily by measuring something called Forced Vital Capacity (FVC) — which is simply the total amount of air a person can breathe out in one go — expressed as a percentage compared to what would be expected for someone of a similar age, sex, and body size. By the end of the study, 15 people in the LTP001 group and 17 in the placebo group had completed the trial. The reported data shows that, on the primary measure, lung function (FVC as a percentage of predicted) declined in both groups by the end of the treatment period — by an average of 3.1 percentage points in the LTP001 group and 1.1 percentage points in the placebo group. For the secondary measures, the reported data shows the actual volume of air exhaled (FVC in millilitres) also fell in both groups — by an average of 120 mL in the LTP001 group and 45.5 mL in the placebo group. A separate secondary measure looked at how long participants went before experiencing a significant decline in lung function, hospitalisation, lung transplant, or death — the reported median time to such an event was 185 days in both groups. Six participants in the LTP001 group and five in the placebo group experienced a drop of 10% or more in their predicted FVC. The reported data also shows a separate measure of how well the lungs transfer gas into the bloodstream (DLCO) declined slightly less in the LTP001 group (−0.167 units) than in the placebo group (−0.334 units). Finally, on a six-minute walking distance test, the LTP001 group reported an average increase of 9.2 metres and the placebo group an average increase of 4.7 metres from the start of the trial. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Interstitial Lung Disease Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are at least 40 years old (male or female)
- You have been diagnosed with a lung condition called IPF (idiopathic pulmonary fibrosis) based on specific medical guidelines
- Your lungs are working at 45% or more of the expected capacity for someone your age and size (based on a breathing test called FVC)
- A measure of how well your lungs transfer oxygen into your blood (called DLCO) is at 25% or above of what is expected
- Your doctor does not expect you to need a lung transplant during the course of this trial
- If you are already taking nintedanib or pirfenidone, you have been on a steady, unchanged dose for at least 8 weeks before joining the trial
Who may not be able to join:
- You have a blockage or obstruction in your airways, or your airways showed a significant response to an inhaler during screening tests
- A scan of your lungs showed that more than 20% of your lungs are affected by a condition called emphysema (air sac damage)
- A scan of your lungs showed that less than 10% of your lungs show signs of scarring (fibrosis)
- You have been diagnosed with a connective tissue disease (a condition affecting joints, skin, or organs, such as lupus or rheumatoid arthritis)
- You have had a sudden, serious worsening of your IPF or another significant health decline in the 3 months before joining the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline to End of Treatment Epoch in Forced Vital Capacity (FVC) Expressed in Percent Predicted
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.